Description

Icatibant acetate is a potent and selective bradykinin B2 receptor antagonist peptide. Bradykinin is a key mediator involved in vasodilation, increased vascular permeability, pain, and inflammation. By competitively inhibiting bradykinin B2 receptors, Icatibant acetate blocks these physiological effects, making it a valuable tool for research into diseases involving bradykinin pathways such as hereditary angioedema (HAE).

Icatibant acetate is a synthetic decapeptide that mimics natural bradykinin receptor antagonists but with enhanced stability and receptor affinity. This compound is extensively studied for its pharmacological effects on vascular biology, inflammatory response modulation, and potential therapeutic interventions in edema and inflammatory disorders.

Produced under GMP conditions with high purity (99.85%), this Icatibant acetate supports reliable and consistent results in experimental and preclinical research.

Product Specifications

Mechanism of Action & Research Applications

Icatibant acetate acts as a selective antagonist of the bradykinin B2 receptor. By preventing bradykinin binding, it inhibits the downstream signaling pathways responsible for vasodilation, increased vascular permeability, pain, and inflammation.

This mechanism makes Icatibant acetate a valuable compound in research on hereditary angioedema (HAE), where excessive bradykinin leads to episodic swelling and edema. It is also used in studies of inflammatory diseases, vascular permeability disorders, and pain modulation.

Side Effects (For Research Reference Only)

In experimental settings, Icatibant acetate may cause minor local irritation or inflammatory responses depending on the model used. It does not carry systemic side effects when used in controlled research environments.

Disclaimer

Icatibant acetate is intended exclusively for laboratory research purposes. It is not approved for diagnostic, therapeutic, or human/veterinary use. Handle with appropriate safety protocols.